Under the stewardship of The Economist editors, our inaugural event on cell and gene therapies convenes industry stakeholders to accelerate access to transformative products.
Cell and gene therapies are redefining the treatment of many diseases, giving hope to patients who previously had no therapeutic options. These treatments can be transformative in the battle against cancer, genetic disorders and rare diseases. In the UK, NICE expects to review 30 new cell and gene therapy products by 2023, with the FDA in the US predicting between 15 and 20 new products will be on the market by 2025. Attendees will learn how healthcare systems and policies need to evolve before these therapies can become mainstream.
Through a series of interactive sessions, industry stakeholders will debate the challenges of bringing these therapies to market—including manufacturing, real-world data collection and their commercial sustainability. Our conference programme examines the potential for a healthcare paradigm shift, as public opinion and patient experience evolve. We will also assess the innovations needed in pricing policies and payments to combat “big sticker” price tags—some products are $2.48 million per dose—and how they limit accessibility.
April 24th – 25th 2023 • Brussels, Belgium
Enabling market access, policy, and delivery
More about the event